Pain Plague Hits Millennials

Doctor with stethoscope holding a warning sign
Photo: Wirestock Creators / Shutterstock

The “disease of kings” is surging again, and younger people are joining the pain.

At a Glance

  • Global gout cases and disability have risen since 1990, across many regions.
  • Researchers report steady increases among people ages 15 to 39 through 2021.
  • Population aging explains part of the rise, but risk also climbed modestly.
  • Urate-lowering treatment works when used to target and maintain safe levels.

Gout’s comeback is real, and the numbers are moving the wrong way

Health data show more people living with gout now than three decades ago. Global estimates based on large burden-of-disease datasets report rising new cases, total cases, and time lived with symptoms. One analysis found global incidence rose from about 3.98 million in 1990 to about 9.40 million in 2021, while the age-standardized rate also increased, though more modestly. That last point matters. Bigger populations mean more cases, but higher rates mean risk itself also climbed.

Media coverage calls it a comeback for a reason. Public-facing reports highlight growth since 1990 and link it to modern diets and weight gain. Those pieces echo a longer research trend that shows more people with gout in many countries, especially where obesity and kidney disease are also rising. The picture that emerges is not hype. It is a chronic disease spreading wider while health systems still underuse simple treatments that prevent attacks.

Younger adults are entering the gout zone

Gout is often seen as a problem for older men. Data now show increases among younger people too. A global analysis tracking ages 15 to 39 reported steady growth in prevalence, new cases, and disability measures through 2021. That shift matters for families and workplaces. A person in their 30s who starts to flare can spend decades cycling through pain, missed work, and joint damage unless someone addresses uric acid early and sticks to a plan.

Kidney health sits at the center of this story. The body dumps uric acid through the kidneys. When that process slips, crystals form in joints and trigger severe pain. A recent study tied a sizable share of the global gout burden to kidney dysfunction, with regional and sex differences that track broader metabolic stress patterns. In plain terms, as diabetes, high blood pressure, and obesity spread, kidneys struggle, and gout follows close behind.

The pain is brutal, but the playbook to stop it is simple

Anyone who has felt a sheet brush a swollen big toe in the night understands the word “excruciating.” That level of pain can push people to the emergency room. The good news is straightforward. Lower the uric acid and keep it low. Clinical guidance recommends titrating urate-lowering medicine until the blood urate drops below 0.36 millimoles per liter. For severe disease with tophi, shoot below 0.30 millimoles per liter. That target-and-hold approach turns off attacks and prevents joint damage.

Diet and weight matter, but willpower is not a cure. Common sense applies: less alcohol, especially beer; fewer high-purine meats; more water; and weight loss if needed. Still, many patients need medicine to reach goal levels. The most practical path blends both: lifestyle choices to lower the load and daily pills to lock in safe urate. That approach aligns with personal responsibility and the basic duty to use proven, low-cost tools that keep people working and out of the hospital.

The bottom line for families, doctors, and policymakers

Rising gout burden strains households and budgets. Missed workdays, emergency visits, and surgeries add up. The fix is not exotic or expensive. Screen high-risk groups, check uric acid, and treat to target. Primary care teams can manage most cases with a simple plan and clear goals. The data confirm the stakes. Total cases have climbed worldwide, risk has ticked up, and younger adults are now in the mix. The cost of waiting is more pain, more damage, and more dollars burned.

Sources:

nypost.com, nature.com, pmc.ncbi.nlm.nih.gov, pubmed.ncbi.nlm.nih.gov, bpac.org.nz, link.springer.com